Safety analysis of whether normal people can take F/TAF for prevention or treatment

Emtricitabine/Tenofovir Alafenamide (F/TAF, full name Emtricitabine/Tenofovir Alafenamide) is a compound antiviral drug containing emtricitabine and tenofovir Alafenamide. It is mainly used to prevent and treat human immunodeficiency virus (HIV) infection. In medicine, Dacovir is often used for pre-exposure prophylaxis (PrEP) for high-risk groups, that is, continuous medication before the risk of infection occurs to significantly reduce the possibility of HIV infection. For normal people without HIV infection, whether Dacovail can be taken for prevention or treatment requires a comprehensive analysis from the perspectives of safety, applicability and risk.

First of all, Dakohui, as a PrEP medication, has been proven to be safe and effective by a large number of studies in high-risk groups (such as those who have high-risk sexual behaviors, those whose partners are HIV positive, etc.). Clinical studies have shown that taking Dakovo according to the recommended dosage can reduce the risk of HIV sexual transmission by more than 90%. Moreover, compared with the earlier F/TDF (emtricitabine/tenofovir disoproxil fumarate), F/TAF is safer in terms of kidney function and bone density, and is especially suitable for people with weak kidney function or risk of osteoporosis.

Secondly, for ordinary people who have no risk of HIV infection, long-term use of Dakovo will not bring additional therapeutic benefits. Although the drug is generally safe, some adverse reactions may still occur, such as mild headache, nausea, diarrhea, fatigue, etc., and a very small number of people may experience abnormal liver and kidney function. In addition, Daqiu is a prescription drug and must be used under the guidance of a doctor, and HIV status and liver and kidney function must be monitored regularly. If normal people take it at will for a long time, it will not only increase the risk of unnecessary drug exposure, but may also cover up the acute HIV infection period or affect future test results, causing a delay in diagnosis.

Finally, for healthy people who are indeed at risk of infection (such as before high-risk exposure, accidental needle sticks by medical staff, etc.), it is safe and scientific to take Dakovac as a preventive measure for a short period of time or according to the recommended regimen after a doctor’s evaluation. But for general low-risk groups, blind use of such antiviral drugs is not necessary. Generally speaking, Dakohui is safe for pre-exposure prophylaxis in normal people, but it must be evaluated by a doctor, standardized medication, and combined with regular testing and risk control; it is not recommended that ordinary people take Dakohui as a "preventive health care drug" on their own to avoid unnecessary health risks and economic burdens.

Reference materials:https://www.drugs.com/